Burroughs Wellcome Co.

British Technology Group Limited

Glaxo Wellcome Inc.

Btp International Limited

Scott David Gorman

Herman Waldmann

Michael Ronald Clark

Stephen Paul Cobbold

Edward G Routledge

Sarah L Bolt

Edward Graham Routledge

An altered antibody chain is produced in which the CDR's of the variable domain of the chain are derived from a first mammalian species. The framework-encoding regions of DNA encoding the variable domain of the first species are mutated so that the mutated framework-encoding regions encode a framework derived from a second different mammalian species. The or each constant domain of the antibody chain, if present, are also derived from the second mammalian species. An antibody which is capable of binding to human CD4 antigen is also provided together with a pharmaceutical composition comprising the antibody.

Chimeric antibody, pharmaceutical composition and process of its production

An altered antibody chain is produced in which the CDR's of the variable domain of the chain are derived from a first mammalian species. The framework-encoding regions of DNA encoding the variable domain of the first species are mutated so that the mutated framework-encoding regions encode a framework derived from a second different mammalian species. The or each constant domain of the antibody chain, if present, are also derived from the second mammalian species.

Altered antibodies and their preparation

An antibody or antibody fragment with a binding affinity for the CD3 antigen, having a human constant region, and human or rat variable framework region, a heavy chain with CDRs having the amino acid sequences:

Antibodies with binding affinity for the CD3 antigen

Humanized anti-CD3 specific antibodies

Growing community of inventors

Cambridge, United Kingdom

Scott David Gorman